# Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia

> **NCT07484204** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Anxo Pharmaceutical Co., Ltd.** · enrollment: 48 (estimated)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** AX251 LAI 45 mg
- **DRUG:** AX251 LAI 90 mg
- **DRUG:** AX251 LAI 135 mg
- **DRUG:** AX251 LAI 180 mg

## Key facts

- **NCT ID:** NCT07484204
- **Lead sponsor:** Anxo Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2028-07
- **Final completion:** 2028-07
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07484204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07484204, "Evaluate Pharmacokinetics, Safety, and Tolerability of AX251 LAI in Patients With Schizophrenia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07484204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*